Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-04958242 in stable schizophrenia
NCT02332798Phase 1Completed
- Sponsor
- Biogen
- Start
- Jan 2015
- Primary completion
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of pesampator in schizophrenia (3 arms), sponsored by Biogen. Primary endpoints: Maximum Observed Plasma Concentration (Single Dose) at Day 1, Maximum Observed Plasma Concentration (Steady State) at Day 21 and 17 more. Started Jan 2015; status: completed.
02
Drugs
pesampator
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02332798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02332798.